Tarsus Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Bobak R. Azamian
- Full Time Employees
- 370
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 15440 Laguna Canyon Road Irvine CA United States of America 92618
- IPO Date
- Oct 16, 2020
- CIK
- 0001819790
- Website
- tarsusrx.com
- Similar Companies
- Business
- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies targeting diseases of the eye and infectious conditions in the United States; its lead commercialized product is XDEMVY (lotilaner ophthalmic solution) 0.25%, the first and only FDA-approved treatment for Demodex blepharitis caused by Demodex mite infestation, as well as for associated meibomian gland disease; the company advances a pipeline of wholly owned lotilaner-based candidates, including TP-04 (lotilaner ophthalmic gel) for ocular rosacea, TP-05 for Lyme disease prophylaxis and community malaria reduction, and lotilaner active pharmaceutical ingredient for additional eye care and infectious disease prevention applications. Founded in 2016 and headquartered in Irvine, California, Tarsus operates primarily in the biotechnology sector with emphasis on eye care and parasitology-driven therapeutics for patients underserved by existing treatments. In recent developments, the company reports robust growth in XDEMVY net product sales, reaching $78.3 million in Q1 2025 (up 217% year-over-year), $118.7 million in Q3 2025 (up 147% year-over-year), and projecting $140-145 million for Q4 2025, supported by expanded payer coverage exceeding 90% of U.S. patients, sales force enhancements, and direct-to-consumer campaigns; Tarsus strengthened its balance sheet with a $135 million public equity offering in Q1 2025, bringing cash reserves to approximately $408 million, while planning Phase 2 initiation for TP-04 in ocular rosacea in H2 2025 and advancing studies for TP-05.
Company News
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
114,458 Shares in Tarsus Pharmaceuticals, Inc. $TARS Bought by Bank of New York Mellon Corp
Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease
Tarsus to Participate in Upcoming Investor Conferences
Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Disease
Tarsus Pharmaceuticals Q2 Earnings Call Highlights
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Caxton Associates LLP Has $1.06 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARS
Tarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts Approaching
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline
Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug
Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101